KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Royalty Pharma (RPRX) over the last 4 years, with Sep 2025 value amounting to $502.9 million.

  • Royalty Pharma's Other Non-Current Liabilities rose 8913.23% to $502.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $502.9 million, marking a year-over-year increase of 8913.23%. This contributed to the annual value of $12.1 million for FY2024, which is 1242.22% up from last year.
  • Latest data reveals that Royalty Pharma reported Other Non-Current Liabilities of $502.9 million as of Q3 2025, which was up 7.66% from $467.1 million recorded in Q2 2025.
  • Royalty Pharma's Other Non-Current Liabilities' 5-year high stood at $502.9 million during Q3 2025, with a 5-year trough of $900,000 in Q4 2023.
  • Over the past 3 years, Royalty Pharma's median Other Non-Current Liabilities value was $12.1 million (recorded in 2024), while the average stood at $97.2 million.
  • In the last 5 years, Royalty Pharma's Other Non-Current Liabilities crashed by 80.55% in 2023 and then skyrocketed by 8,913.23% in 2025.
  • Over the past 4 years, Royalty Pharma's Other Non-Current Liabilities (Quarterly) stood at $2.5 million in 2022, then slumped by 64.00% to $900,000 in 2023, then surged by 1,242.22% to $12.1 million in 2024, then surged by 8,913.23% to $502.9 million in 2025.
  • Its Other Non-Current Liabilities was $502.9 million in Q3 2025, compared to $467.1 million in Q2 2025 and $17.9 million in Q1 2025.